

Q1. Within your trust, how many patients currently have a diagnosis for

Fabry Disease

Gaucher Disease

MPS II (Hunter Syndrome)

NHS Dumfries and Galloway do not hold this information centrally; therefore this request is refused under section 17 of FOISA

Q2. Of the patients above, how many have been newly diagnosed within the past 3 months for

Fabry Disease

Gaucher Disease

MPS II (Hunter Syndrome)

NHS Dumfries and Galloway do not hold this information centrally; therefore this request is refused under section 17 of FOISA

Q3. How many patients (including any patients whose treatment is on hold due to Covid-shielding) are being treated at this point in time with:

Replagal (agalsidase alpha) Not in data

Fabrazyme (agalsidase beta) less than 5 (this data is exempt under section 38(1)(b) as it is potentially identifiable information)

Galafold (migalastat) Not in data

VPRIV (velaglucerase alfa) Not in data

Cerezyme (imiglucerase) Not in data

Cerdelga (eliglustat) Not in data

Zavesca (miglustat) Not in data

Any other treatment for Fabry disease [please state which treatments] NHS Dumfries and Galloway do not hold this information centrally; therefore this request is refused under section 17 of FOISA

Any other treatment for Gaucher disease [please state which treatments] NHS Dumfries and Galloway do not hold this information centrally; therefore this request is refused under section 17 of FOISA

Q4. Of the patients being treated for Fabry disease can you please provide the numbers of patients being treated through homecare? This data is exempt under section 38(1)(b) as it is potentially identifiable information